AngioDynamics, Inc. (NASDAQ:ANGO) Stock Rated “Moderate Buy” by Wall Street Analysts

Shares of AngioDynamics, Inc. (NASDAQ:ANGO) have received an average recommendation of “Moderate Buy” from the five ratings firms that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, two have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $19.00.

A number of equities analysts have recently weighed in on the stock. Canaccord Genuity Group reaffirmed a “buy” rating and set a $20.00 price target on shares of AngioDynamics in a research note on Friday, October 9th. Wall Street Zen cut shares of AngioDynamics from a “buy” rating to a “hold” rating in a research note on Saturday, October 10th. HC Wainwright decreased their price objective on shares of AngioDynamics from $19.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday, October 13th. Zacks Research raised shares of AngioDynamics from a “strong sell” rating to a “hold” rating in a report on Monday, October 5th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a research report on Thursday.

Insider Activity

In other news, SVP Warren Jr sold 23,370 shares of AngioDynamics stock in a transaction that occurred on Thursday, July 30th. The shares were sold at an average price of $14.72, for a total transaction of $344,006.40. Following the completion of the sale, the senior vice president directly owned 64,745 shares in the company, valued at approximately $953,046.40. This trade represents a 26.52% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 6.00% of the company’s stock.

Institutional Investors Weigh In On AngioDynamics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Integrated Wealth Concepts LLC acquired a new position in shares of AngioDynamics during the 2nd quarter worth $38,000. Corient Private Wealth LP purchased a new stake in shares of AngioDynamics in the 2nd quarter worth about $134,000. Public Employees Retirement System of Ohio purchased a new stake in shares of AngioDynamics in the 2nd quarter worth about $64,000. Bank of America Corp DE acquired a new stake in AngioDynamics in the 2nd quarter valued at about $4,490,000. Finally, Gallagher Fiduciary Advisors LLC acquired a new stake in AngioDynamics in the 2nd quarter valued at about $589,000. Institutional investors and hedge funds own 89.43% of the company’s stock.

AngioDynamics Stock Up 1.3%

Shares of ANGO stock opened at $11.39 on Thursday. The business’s fifty day moving average price is $14.84 and its 200 day moving average price is $13.13. AngioDynamics has a 1-year low of $9.39 and a 1-year high of $16.29.

AngioDynamics (NASDAQ:ANGO) last released its earnings results on Thursday, October 8th. The medical instruments supplier reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.07. AngioDynamics had a negative return on equity of 4.49% and a negative net margin of 10.12%. The company had revenue of $80.92 million during the quarter, compared to the consensus estimate of $80.51 million. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. As a group, equities research analysts anticipate that AngioDynamics will post -0.26 EPS for the current year.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical device company that develops, manufactures and markets minimally invasive products for use in vascular disease, vascular access and oncology. Its technologies are designed to help physicians treat blood clots, restore blood flow, manage vascular access and ablate targeted tissue.

The company’s portfolio includes the Auryon platform for atherectomy, which uses laser technology to treat peripheral arterial disease; the AngioVac and AlphaVac systems for removing thrombus and other unwanted material from blood vessels; and BioSentry products used to seal biopsy tracts.